Copyright © 2002 by the European Society of Cardiology.
Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes
a Department of Cardiology, Academic Hospital, Uppsala, Sweden
b Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
c Duke CRI, Durham, NC, USA
d Department of Cardiology, Aarhus, Amtssygehus Aarhus, Denmark
e Heart-lung center, Ullevál Hospital, Oslo, Norway
f University Hospital Internal Medicin, Helsinki, Finland
g University Hospital, Basel, Switzerland
h Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands
revised March 25, 2002; accepted March 27, 2002
Abstract
Aims The safety and efficacy of abciximab in addition to low-molecular-weight-heparin as the primary medical treatment of acute coronary syndromes has not previously been investigated.
Methods and Results The GUSTO IV–ACS trial included 7800 patients with chest pain and either ST-segment depression or a positive troponin test. They were randomized to abciximab for 24h, 48h or placebo. In the dalteparin substudy, 974 patients received 5 days of s.c. dalteparin, instead of a 48h infusion of unfractionated heparin (UFH). Major and minor bleedings were more frequent for abciximab (24 and 48h combined) than placebo both in the dalteparin (abciximab 5·0% vs placebo 1·8% P<0·05) and in the UFH cohort (3·8% vs 1·8% P<0·001). However, stroke rates were low, 
0·6%. At 30 days there were no significant differences in the rate of death or MI, either in the dalteparin (abciximab 9·6% vs placebo 11·3%: O.R. 0·85; 95% C.I. 0·58–1·25) or in the UFH cohort (8·5% vs 7·6%: O.R.; 1·12: 0·95–1·34).
Conclusion Treatment with abciximab, aspirin and s.c. dalteparin is associated with a low risk of major side effects and is as safe as the combination of abciximab and UFH. Without early coronary intervention there is no indication for abciximab treatment. Copyright 2002 The European Society of Cardiology. Published by Elsevier Science Ltd. All rights reserved.
Key Words: Angina, myocardial infarction, coagulation, heparin
f1 Correspondence: Stefan James MD, Department of Cardiology, Thoraxcenter, Academic Hospital, 751 85 Uppsala, Sweden
References
- Lancet. 1996;347:561–568[CrossRef][Web of Science][Medline]
- Eikelboom JW, Anand SS, Malmberg K. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet. 2000;355:1936–1942[CrossRef][Web of Science][Medline]
- Antman EM, Cohen M, Radley D. Assessment of the treatment effect of enoxaparin for unstable angina/ non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation. 1999;100:1602–1608
[Abstract/Free Full Text] - N Engl J Med. 1994;330:956–961
[Abstract/Free Full Text] - Lancet. 1997;349:1429–1435[CrossRef][Web of Science][Medline]
- N Engl J Med. 1997;336:1689–1696
[Abstract/Free Full Text] - Lancet. 2001;357:1915–1924[CrossRef][Web of Science][Medline]
- N Engl J Med. 1998;338:1488–1497
[Abstract/Free Full Text] - N Engl J Med. 1998;339:436–443
[Abstract/Free Full Text] - Boersma E, Harrington RA, Moliterno DJ. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet. 2002;359:189–198[CrossRef][Web of Science][Medline]
- Braunwald E, Antman EM, Beasley JW. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on the management of patients with unstable angina). Circulation. 2000;102:1193–1209
[Free Full Text] - Bertrand ME, Simoons ML, Fox KA. Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation; recommendations of the Task Force of the European Society of Cardiology. Eur Heart J. 2000;21:1406–1432
[Free Full Text] - Rao AK, Pratt C, Berke A. Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 1988;11:1–11[Abstract]
- Ferguson JJ, Kereiakes DJ, Adgey AA. Safe use of platelet GP IIb/IIIa inhibitors. Eur Heart J. 1998;19:D40–51
- Blankenship JC. Bleeding complications of glycoprotein IIb-IIIa receptor inhibitors. Am Heart J. 1999;138:287–296[CrossRef][Medline]
- Kereiakes DJ, Fry E, Matthai W. Combination enoxaparin and abciximab therapy during coronary intervention: ‘NICE guys finish first’. J Invasive Cardiol. 2000;12:1A–5A
- Cohen EM, Theroux P, Frey MJ. Anti-thrombotic combination using Tirofiban and Enoxaparin. The ACUTE II study. 2000;102:
- Kereiakes DJ, Kleiman NS, Fry E. Dalteparin in combination with abciximab during coronary intervention. Am Heart J. 2001;141:348–352[CrossRef][Web of Science][Medline]
- Cannon CP, Weintraub WS, Demopoulos LA. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001;344:1879–1887
[Abstract/Free Full Text]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. A. Harrington, R. C. Becker, C. P. Cannon, D. Gutterman, A. M. Lincoff, J. J. Popma, G. Steg, G. H. Guyatt, and S. G. Goodman Antithrombotic Therapy for Non-ST-Segment Elevation Acute Coronary Syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 670S - 707S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Authors/Task Force Members, J.-P. Bassand, C. W. Hamm, D. Ardissino, E. Boersma, A. Budaj, F. Fernandez-Aviles, K. A.A. Fox, D. Hasdai, E. M. Ohman, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology Eur. Heart J., July 1, 2007; 28(13): 1598 - 1660. [Full Text] [PDF]
|
|
|
|
|
|
R. De Caterina, S. Husted, L. Wallentin, G. Agnelli, F. Bachmann, C. Baigent, J. Jespersen, S. D. Kristensen, G. Montalescot, A. Siegbahn, et al. Anticoagulants in heart disease: current status and perspectives Eur. Heart J., April 10, 2007; (2007) ehl492v1. [Full Text] [PDF]
|
|
|
|
 |
|
 X. Yang, K. P. Alexander, A. Y. Chen, M. T. Roe, R. G. Brindis, S. V. Rao, W. B. Gibler, E. M. Ohman, E. D. Peterson, and for the CRUSADE Investigators The Implications of Blood Transfusions for Patients With Non-ST-Segment Elevation Acute Coronary Syndromes: Results From the CRUSADE National Quality Improvement Initiative J. Am. Coll. Cardiol., October 18, 2005; 46(8): 1490 - 1495. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. de Lemos, M. A. Blazing, S. D. Wiviott, W. E. Brady, H. D. White, K. A.A. Fox, J. Palmisano, K. E. Ramsey, D. W. Bilheimer, E. F. Lewis, et al. Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial Eur. Heart J., October 1, 2004; 25(19): 1688 - 1694. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Harrington, R. C. Becker, M. Ezekowitz, T. W. Meade, C. M. O'Connor, D. A. Vorchheimer, and G. H. Guyatt Antithrombotic Therapy for Coronary Artery Disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 513S - 548S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. C. Wong, R. P. Giugliano, and E. M. Antman Use of Low-Molecular-Weight Heparins in the Management of Acute Coronary Artery Syndromes and Percutaneous Coronary Intervention JAMA, January 15, 2003; 289(3): 331 - 342. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Bertrand, M. L. Simoons, K. A.A. Fox, L. C. Wallentin, C. W. Hamm, E. McFadden, P. J. De Feyter, G. Specchia, and W. Ruzyllo Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation Eur. Heart J., December 1, 2002; 23(23): 1809 - 1840. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||